Anticoagulants have been the mainstay of therapy for the long-term and acute prevention and treatment of various types of thromboembolic disorders. The prevention of thromboembolic stroke among patients with persistent atrial fibrillation (AF) has been one of the main indications for oral anticoagulation therapy. At least 2.6 million people are living with atrial fibrillation, and it is estimated to reach 12 million people by the year 2050, states American Heath Health Association.
